Photo: Courtesy of Teva
The US Federal Trade Commission (FTC) has approved a final order that Teva’s acquisition of Allergan’s generic pharmaceutical business for $40.5 billion would be anticompetitive.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
FTC, Teva, Allergan, divestiture,
